Atara Biotherapeutics Q3 Loss, Stock Fluctuations
Update: 2025-11-12
Description
Atara Biotherapeutics, a California-based drug developer, reported a Q3 loss of $4.3 million, or 32 cents per share, alongside $3.5 million in revenue. Despite a year-to-date stock drop of nearly 6%, the companys shares have risen by almost 7% over the past twelve months, reflecting the volatile nature of the biotech market.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
